Risk and pharmacoeconomic analyses of the injectable medication process in the paediatric and neonatal intensive care units

Details

Ressource 1Download: serval:BIB_0E8AC1007E27.P001 (351.71 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_0E8AC1007E27
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Risk and pharmacoeconomic analyses of the injectable medication process in the paediatric and neonatal intensive care units
Journal
International Journal For Quality In Health Care : Journal of the International Society For Quality In Health Care
Author(s)
De Giorgi I., Fonzo-Christe C., Cingria L., Caredda B., Meyer V., Pfister R.E., Bonnabry P.
ISSN
1464-3677 (Electronic)
ISSN-L
1353-4505
Publication state
Published
Issued date
2010
Volume
22
Number
3
Pages
170-178
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
OBJECTIVE: To analyse safety risks in injectable medications. To assess the potential impact and pharmacoeconomic aspects of safety tools.
DESIGN: The injectable drug process was prospectively assessed using a failure modes, effects and criticality analysis. Criticality indexes were estimated based on their likelihood of occurrence, detection probability and potential severity. The impact of 10 safety tools on the criticality index was calculated and extrapolated to all drugs injected daily. Yearly costs for a reduction in criticality by 1 point (=1 quali) per day were estimated.
SETTING: Paediatric and neonatal intensive care units in a University Hospital.
PARTICIPANTS: Two paediatric nurses, a neonatologist, three hospital pharmacists.
INTERVENTIONS: Qualitative and quantitative risk assessment.
MAIN OUTCOME MEASURES: Failure modes, criticality indexes, cost-efficacy ratios.
RESULTS: Thirty-one failure modes identified, with the mean of their entire criticality indexes totalling 4540. The most critical failure mode was microbial contamination. The following gains were predicted: 1292 quali (46 500 per day by extrapolation) from ready-to-use syringes, 1201 (72 060) by employing a clinical pharmacist, 996 (59 780) from double check by nurses and 984 (59 040) with computerized physician order entry. The best cost-efficacy ratios were obtained for a clinical pharmacist (1 quali = 0.54 euros), double check (1 quali = 0.71 euros) and ready-to-use syringes (1 quali = 0.72 euros). Computerized physician order entry showed the worst cost-efficacy ratio due to a very high investment costs (1 quali = 22.47 euros).
CONCLUSION: Based on our risk and pharmacoeconomic analyses, clinical pharmacy and ready-to-use syringes appear as the most promising safety tools.
Keywords
Hospitals, University/organization & administration, Injections/adverse effects, Injections/economics, Injections/methods, Intensive Care Units, Neonatal/organization & administration, Intensive Care Units, Pediatric/economics, Intensive Care Units, Pediatric/organization & administration, Medication Errors/economics, Medication Errors/prevention & control, Pharmacy Service, Hospital/economics, Pharmacy Service, Hospital/organization & administration, Safety Management/economics, Safety Management/organization & administration
Pubmed
Web of science
Open Access
Yes
Create date
13/07/2018 10:00
Last modification date
25/09/2019 7:08
Usage data